Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15184383 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Humphries LA, et al. (2004) Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. J Biol Chem 279, 37651-61 15184383
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y753-p - PLCG2 (human)
Orthologous residues
PLCG2 (human): Y753‑p, PLCG2 (mouse): Y753‑p, PLCG2 (rat): Y753‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody
 Relevant cell lines - cell types - tissues:  A20 (B lymphocyte), RAMOS (B lymphocyte), XLA (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Lck (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
anti-IgM increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

Y759-p - PLCG2 (human)
Orthologous residues
PLCG2 (human): Y759‑p, PLCG2 (mouse): Y759‑p, PLCG2 (rat): Y759‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody
 Relevant cell lines - cell types - tissues:  A20 (B lymphocyte), RAMOS (B lymphocyte), XLA (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Lck (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
anti-IgM increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

Y1197-p - PLCG2 (human)
Orthologous residues
PLCG2 (human): Y1197‑p, PLCG2 (mouse): Y1197‑p, PLCG2 (rat): Y1197‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, phospho-antibody
 Relevant cell lines - cell types - tissues:  A20 (B lymphocyte), RAMOS (B lymphocyte), XLA (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Lck (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
anti-IgM increase

Y1217-p - PLCG2 (human)
Orthologous residues
PLCG2 (human): Y1217‑p, PLCG2 (mouse): Y1217‑p, PLCG2 (rat): Y1217‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, phospho-antibody
 Relevant cell lines - cell types - tissues:  A20 (B lymphocyte), RAMOS (B lymphocyte), XLA (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Lck (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
anti-IgM increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.